Humanigen
Humanigen is a biopharmaceutical company dedicated to developing innovative therapies. Their mission is to create effective treatments to improve patient outcomes. They focus on research and development in the biotech sector.
Industries
Nr. of Employees
small (1-50)
Humanigen
Burlingame, California, United States, North America
Patents
Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
US-11130805-B2
View DetailsMethod of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US-10927168-B2
View DetailsMethod of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US-10899831-B2
View DetailsMethods of treating immunotherapy-related toxicity using a GM-CSF antagonist
US-10870703-B2
View Details
Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
US-11130805-B2
View DetailsMethod of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US-10927168-B2
View DetailsMethod of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US-10899831-B2
View DetailsMethods of treating immunotherapy-related toxicity using a GM-CSF antagonist
US-10870703-B2
View DetailsProducts
Clinical-stage monoclonal antibody targeting GM-CSF
A human monoclonal antibody candidate designed to neutralize granulocyte–macrophage colony-stimulating factor (GM-CSF) to reduce cytokine-driven inflammation and related clinical complications; advanced through preclinical studies and clinical trials for acute respiratory and immunotherapy-associated cytokine release conditions.
LENZ
LENZ is a monoclonal antibody product currently filled as 10mg/ml into a 10ml vial, intended for treatment of hypoxic hospitalized COVID-19 pneumonia patients, prevention and treatment of CAR-T CRS and neurotoxicity, and improvement in CAR-T efficacy.
LENZ 4 (lenzilumab)
LENZ is a variant-agnostic immunomodulatory antibody developed by Humanigen that neutralizes human GM-CSF, addressing hyperinflammatory conditions such as cytokine release syndrome and cytokine storm, with demonstrated benefit in COVID-19 patients.
LENZ® (lenzilumab)
A proprietary Humaneered® first-in-class monoclonal antibody with best-in-class specificity and affinity that neutralizes GM-CSF to prevent signaling through its receptor, used in combination with azacitidine in the treatment of chronic myelomonocytic leukemia (CMML).
Lenzilumab™
Lenzilumab is a clinical-stage immunomodulatory monoclonal antibody drug candidate developed by Humanigen for the treatment of hospitalized COVID-19 patients to improve survival without the need for invasive mechanical ventilation by preventing cytokine storm.
HGEN005
HGEN005 is a monoclonal antibody product in early clinical development (Phase 1/2) for eosinophilic diseases.
Clinical-stage monoclonal antibody targeting GM-CSF
A human monoclonal antibody candidate designed to neutralize granulocyte–macrophage colony-stimulating factor (GM-CSF) to reduce cytokine-driven inflammation and related clinical complications; advanced through preclinical studies and clinical trials for acute respiratory and immunotherapy-associated cytokine release conditions.
LENZ
LENZ is a monoclonal antibody product currently filled as 10mg/ml into a 10ml vial, intended for treatment of hypoxic hospitalized COVID-19 pneumonia patients, prevention and treatment of CAR-T CRS and neurotoxicity, and improvement in CAR-T efficacy.
LENZ 4 (lenzilumab)
LENZ is a variant-agnostic immunomodulatory antibody developed by Humanigen that neutralizes human GM-CSF, addressing hyperinflammatory conditions such as cytokine release syndrome and cytokine storm, with demonstrated benefit in COVID-19 patients.
LENZ® (lenzilumab)
A proprietary Humaneered® first-in-class monoclonal antibody with best-in-class specificity and affinity that neutralizes GM-CSF to prevent signaling through its receptor, used in combination with azacitidine in the treatment of chronic myelomonocytic leukemia (CMML).
Lenzilumab™
Lenzilumab is a clinical-stage immunomodulatory monoclonal antibody drug candidate developed by Humanigen for the treatment of hospitalized COVID-19 patients to improve survival without the need for invasive mechanical ventilation by preventing cytokine storm.
HGEN005
HGEN005 is a monoclonal antibody product in early clinical development (Phase 1/2) for eosinophilic diseases.
Services
Sponsor-led clinical development services covering protocol design, trial execution, clinical operations, and data analysis for clinical-stage biologics.
Sponsor-led clinical development services covering protocol design, trial execution, clinical operations, and data analysis for clinical-stage biologics.
Expertise Areas
- Clinical trial management
- Monoclonal antibody therapeutics
- Cytokine biology and GM-CSF modulation
- Translational biomarker development
Key Technologies
- Monoclonal antibody platforms
- Cytokine and multiplex immunoassays
- Flow cytometry
- Preclinical in vivo disease models